Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pragmatic trial on optimized rifampicin dose in tuberculosis
2022-000632-27Phase 3Active
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rifampicin in pulmonary tuberculosis (TB) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Incidence of hepatotoxicity at 6 months. Started Apr 2022; status: active.
02
Drugs
rifampicin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on 2022-000632-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000632-27.